Table 3. Clinicopathological characteristics of part-solid nodules after two propensity-score matching by total lesion size and solid component size, respectively.
| Characteristic | PSN, after the first PSM | PSN, after the second PSM | |||||
|---|---|---|---|---|---|---|---|
| GGO-predominant (n=157, CTR ≤0.5) | Solid-predominant (n=157, CTR >0.5) | P value | GGO-predominant (n=73, CTR <0.5) | Solid-predominant (n=73, CTR >0.5) | P value | ||
| Sex | 0.904 | 0.603 | |||||
| Female | 106 (67.5%) | 107 (68.2%) | 46 (63.0%) | 49 (67.1%) | |||
| Male | 51 (32.5%) | 50 (31.8%) | 27 (37.0%) | 24 (32.9%) | |||
| Age, year | 60.9±9.1 | 60.8±9.6 | 0.918 | 62.6±8.8 | 60.0±9.5 | 0.105 | |
| Smoking history | 1.000 | 1.000 | |||||
| Smoker | 11 (7.0%) | 11 (7.0%) | 2 (2.7%) | 3 (4.1%) | |||
| Non-smoker | 146 (93.0%) | 146 (93.0%) | 71 (97.3%) | 70 (95.9%) | |||
| ASA score | 0.275 | 0.593 | |||||
| 1 | 68 (43.3%) | 71 (45.2%) | 28 (38.4%) | 34 (46.6%) | |||
| 2 | 83 (52.9%) | 74 (47.1%) | 42 (57.5%) | 36 (49.3%) | |||
| 3 | 6 (3.8%) | 12 (7.6%) | 3 (4.1%) | 3 (4.1%) | |||
| BMI, kg/m2 | 22.9±2.9 | 22.6±3.1 | 0.471 | 22.5±2.7 | 22.6±2.4 | 0.702 | |
| FEV1% predicted | 0.550 | 0.820 | |||||
| ≥0.8 | 132 (84.1%) | 128 (81.5%) | 62 (84.9%) | 61 (83.6%) | |||
| <0.8 | 25 (15.9%) | 29 (18.5%) | 11 (15.1%) | 12 (16.4%) | |||
| Solid component size, mm | 6.5±2.9 | 12.7±5.0 | <0.001 | 8.7±2.6 | 8.8±2.8 | 0.878 | |
| Total lesion size, mm | 17.9±6.1 | 18.6±6.3 | 0.340 | 21.3±5.6 | 14.0±4.6 | <0.001 | |
| Surgery | 0.143 | 0.641 | |||||
| Wedge resection | 24 (15.3%) | 28 (17.8%) | 13 (17.8%) | 13 (17.8%) | |||
| Segmentectomy | 33 (21.0%) | 20 (12.7%) | 13 (17.8%) | 9 (12.3%) | |||
| Lobectomy | 100 (63.7%) | 109 (69.4%) | 47 (64.4%) | 51 (69.9%) | |||
| Lymph node resection | 0.909 | 0.740 | |||||
| SNS | 69 (43.9%) | 68 (43.3%) | 35 (47.9%) | 33 (45.2%) | |||
| SND | 88 (56.1%) | 89 (56.7%) | 38 (52.1%) | 40 (54.8%) | |||
| Histological subtype | <0.001 | 0.312 | |||||
| NIA | 53 (33.8%) | 21 (13.4%) | 13 (17.8%) | 18 (24.7%) | |||
| IA | 104 (66.2%) | 136 (86.6%) | 60 (82.2%) | 55 (75.3%) | |||
| LVI | 1 (0.6%) | 8 (5.1%) | 0.042 | 0 (0%) | 0 (0%) | - | |
| VPI | 2 (1.3%) | 14 (8.9%) | 0.002 | 3 (4.1%) | 3 (4.1%) | 1.000 | |
| Pathological N1/N2 | 1 (0.6%) | 16 (10.2%) | <0.001 | 0 (0%) | 0 (0%) | - | |
PSN, part-solid nodule; PSM, propensity-score matching; GGO, ground glass opacity; CTR, consolidation-to-tumor ratio; ASA, American Society of Anesthesiologists; BMI, body mass index; FEV1, forced expiratory volume in 1 second; SNS, systematic lymph node sampling; SND, systematic lymph node dissection; NIA, noninvasive adenocarcinoma; IA, invasive adenocarcinoma; LVI, lymphovascular invasion; VPI, visceral pleural invasion.